Literature DB >> 23715523

Neutrophilic urticaria with systemic inflammation: a case series.

Hrishikesh Belani1, Lianne Gensler, Urmila Bajpai, Eric Meinhardt, Jonathan Graf, Laura Pincus, Kieron S Leslie.   

Abstract

IMPORTANCE: Predominantly neutrophilic infiltrates are seen in a subset of patients with urticaria. The lesions tend to be less itchy and poorly responsive to standard therapy, including antihistamines. We describe 2 patients having neutrophilic urticaria with systemic inflammation (NUSI) without known connective tissue disorder or malignancy. We propose the term NUSI to help classify a previously undefined multisystemic inflammatory entity likely mediated by interleukin 1 (IL-1). OBSERVATIONS: Patient 1, a 47-year-old woman, was seen with urticaria and associated night sweats, fevers, and polyarticular arthritis. Acute-phase reactants were elevated with worsening of symptoms. Initial treatment with a combination of topical and systemic corticosteroids, antihistamines, and immunosuppressants was unsuccessful. A 100% clinical resolution was achieved with anakinra, an IL-1 receptor antagonist. Patient 2, a 24-year-old woman, was seen with urticaria and associated joint pain and swelling. Initial treatment included a combination of antihistamines, colchicine, and dapsone. Only colchicine provided moderate benefit but was stopped because of significant gastrointestinal tract discomfort. Anakinra was initiated; the patient achieved 100% control while receiving daily therapy. CONCLUSIONS AND RELEVANCE: The diagnosis of NUSI is important to consider in patients who are seen with antihistamine-resistant urticaria in combination with systemic inflammatory symptoms. Interleukin 1 blockade is a viable option for therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23715523     DOI: 10.1001/jamadermatol.2013.2705

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  10 in total

1.  Investigation of patient-specific characteristics associated with treatment outcomes for chronic urticaria.

Authors:  Priyal Amin; Linda Levin; Sarah J Holmes; Jillian Picard; Jonathan A Bernstein
Journal:  J Allergy Clin Immunol Pract       Date:  2015-02-11

Review 2.  Colchicine: an ancient drug with novel applications.

Authors:  B Dasgeb; D Kornreich; K McGuinn; L Okon; I Brownell; D L Sackett
Journal:  Br J Dermatol       Date:  2018-01-03       Impact factor: 9.302

Review 3.  An expanding role for interleukin-1 blockade from gout to cancer.

Authors:  Charles Anthony Dinarello
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

Review 4.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

5.  Neutrophilic Urticaria with Systemic Inflammation Associated with Immunoglobulin A Myeloma.

Authors:  Héloïse Paugoy; Anne Saussine; Laure Frumholtz; Maxime Battistella; Marie Jachiet; Jacqueline Rivet; Clémence Lepelletier; Lucie Duverger; Martine Bagot; Alexis Talbot; Bertrand Arnulf; Jean-David Bouaziz
Journal:  Acta Derm Venereol       Date:  2021-04-27       Impact factor: 3.875

6.  Urticarial exanthem associated with Capnocytophaga canimorsus bacteremia after a dog bite.

Authors:  Christian S Jordan; Una Miniter; Kevin Yarbrough; Stephanie J Mengden
Journal:  JAAD Case Rep       Date:  2016-03-03

7.  Romidepsin-induced neutrophilic urticaria.

Authors:  Brian Scott; Heather Wickless
Journal:  JAAD Case Rep       Date:  2016-07-14

8.  A case of Schnitzler's syndrome without monoclonal gammopathy successfully treated with canakinumab.

Authors:  Yuya Fujita; Tomoyuki Asano; Akira Sakai; Natsumi Norikawa; Toshiyuki Yamamoto; Haruki Matsumoto; Shuzo Sato; Jumpei Temmoku; Makiko Yashiro-Furuya; Naoki Matsuoka; Hiroshi Watanabe; Kiyoshi Migita
Journal:  BMC Musculoskelet Disord       Date:  2021-03-08       Impact factor: 2.362

9.  Interleukin 1-β, interleukin-1 receptor antagonist, and interleukin 18 in children with acute spontaneous urticaria.

Authors:  E Machura; M Szczepańska; B Mazur; M Barć-Czarnecka; A Kasperska-Zając
Journal:  Biomed Res Int       Date:  2013-12-29       Impact factor: 3.411

Review 10.  Anakinra Therapy for Non-cancer Inflammatory Diseases.

Authors:  Giulio Cavalli; Charles A Dinarello
Journal:  Front Pharmacol       Date:  2018-11-06       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.